Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Insights into the Regulatory Role of Non-coding RNAs in Cancer Metabolism.

Beltrán-Anaya FO, Cedro-Tanda A, Hidalgo-Miranda A, Romero-Cordoba SL.

Front Physiol. 2016 Aug 8;7:342. doi: 10.3389/fphys.2016.00342. eCollection 2016. Review.

2.

c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma.

Granito A, Guidetti E, Gramantieri L.

J Hepatocell Carcinoma. 2015 Apr 24;2:29-38. doi: 10.2147/JHC.S77038. eCollection 2015. Review.

3.

New insights on the role of epigenetic alterations in hepatocellular carcinoma.

Frau M, Feo CF, Feo F, Pascale RM.

J Hepatocell Carcinoma. 2014 Jun 12;1:65-83. doi: 10.2147/JHC.S44506. eCollection 2014. Review.

4.

MicroRNA-548a-5p promotes proliferation and inhibits apoptosis in hepatocellular carcinoma cells by targeting Tg737.

Zhao G, Wang T, Huang QK, Pu M, Sun W, Zhang ZC, Ling R, Tao KS.

World J Gastroenterol. 2016 Jun 21;22(23):5364-73. doi: 10.3748/wjg.v22.i23.5364.

5.

Expression of miR-199a-3p in human adipocytes is regulated by free fatty acids and adipokines.

Gu N, You L, Shi C, Yang L, Pang L, Cui X, Ji C, Zheng W, Guo X.

Mol Med Rep. 2016 Aug;14(2):1180-6. doi: 10.3892/mmr.2016.5379. Epub 2016 Jun 8.

6.

Accuracy of novel diagnostic biomarkers for hepatocellular carcinoma: An update for clinicians (Review).

Reichl P, Mikulits W.

Oncol Rep. 2016 Aug;36(2):613-25. doi: 10.3892/or.2016.4842. Epub 2016 Jun 1.

7.

Serum microRNA-199a/b-3p as a predictive biomarker for treatment response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.

Luo Z, Feng C, Hu P, Chen Y, He XF, Li Y, Zhao J.

Onco Targets Ther. 2016 May 4;9:2667-74. doi: 10.2147/OTT.S98408. eCollection 2016.

8.

Oncomirs miRNA-221/222 and Tumor Suppressors miRNA-199a/195 Are Crucial miRNAs in Liver Cancer: A Systematic Analysis.

Li Y, Di C, Li W, Cai W, Tan X, Xu L, Yang L, Lou G, Yan Y.

Dig Dis Sci. 2016 Aug;61(8):2315-27. doi: 10.1007/s10620-016-4156-8. Epub 2016 May 7.

9.

Transcriptomic and CRISPR/Cas9 technologies reveal FOXA2 as a tumor suppressor gene in pancreatic cancer.

Vorvis C, Hatziapostolou M, Mahurkar-Joshi S, Koutsioumpa M, Williams J, Donahue TR, Poultsides GA, Eibl G, Iliopoulos D.

Am J Physiol Gastrointest Liver Physiol. 2016 Jun 1;310(11):G1124-37. doi: 10.1152/ajpgi.00035.2016. Epub 2016 May 5.

PMID:
27151939
10.

Mechanisms of doxorubicin resistance in hepatocellular carcinoma.

Cox J, Weinman S.

Hepat Oncol. 2016 Jan 1;3(1):57-59.

PMID:
26998221
11.

miRNA Deregulation in Cancer Cells and the Tumor Microenvironment.

Rupaimoole R, Calin GA, Lopez-Berestein G, Sood AK.

Cancer Discov. 2016 Mar;6(3):235-46. doi: 10.1158/2159-8290.CD-15-0893. Epub 2016 Feb 10. Review.

12.

Development of MicroRNA Therapeutics for Hepatocellular Carcinoma.

Aravalli RN.

Diagnostics (Basel). 2013 Mar 15;3(1):170-91. doi: 10.3390/diagnostics3010170. Review.

13.

MicroRNAs Expressed during Viral Infection: Biomarker Potential and Therapeutic Considerations.

Louten J, Beach M, Palermino K, Weeks M, Holenstein G.

Biomark Insights. 2016 Jan 18;10(Suppl 4):25-52. doi: 10.4137/BMI.S29512. eCollection 2015. Review.

14.

MicroRNA-mediated interactions between host and hepatitis C virus.

Li H, Jiang JD, Peng ZG.

World J Gastroenterol. 2016 Jan 28;22(4):1487-96. doi: 10.3748/wjg.v22.i4.1487. Review.

15.

MiR-130a-3p regulates cell migration and invasion via inhibition of Smad4 in gemcitabine resistant hepatoma cells.

Liu Y, Li Y, Wang R, Qin S, Liu J, Su F, Yang Y, Zhao F, Wang Z, Wu Q.

J Exp Clin Cancer Res. 2016 Jan 27;35:19. doi: 10.1186/s13046-016-0296-0.

16.

Interplay Between Metabolism and Oncogenic Process: Role of microRNAs.

Arora A, Singh S, Bhatt AN, Pandey S, Sandhir R, Dwarakanath BS.

Transl Oncogenomics. 2015 Dec 29;7:11-27. doi: 10.4137/TOG.S29652. eCollection 2015. Review.

17.

Microtargeting cancer metabolism: opening new therapeutic windows based on lipid metabolism.

Gómez de Cedrón M, Ramírez de Molina A.

J Lipid Res. 2016 Feb;57(2):193-206. doi: 10.1194/jlr.R061812. Epub 2015 Dec 2. Review.

PMID:
26630911
18.

miR-214/199a/199a* cluster levels predict poor survival in hepatocellular carcinoma through interference with cell-cycle regulators.

Wang P, Chen S, Fang H, Wu X, Chen D, Peng L, Gao Z, Xie C.

Oncotarget. 2016 Jan 5;7(1):929-45. doi: 10.18632/oncotarget.6137.

19.

MicroRNAs as Important Players in Host-hepatitis B Virus Interactions.

Kitab B, Alj HS, Ezzikouri S, Benjelloun S.

J Clin Transl Hepatol. 2015 Jun 28;3(2):149-61. doi: 10.14218/JCTH.2015.00002. Epub 2015 Jun 15. Review.

20.

MicroRNAs: Emerging Novel Clinical Biomarkers for Hepatocellular Carcinomas.

Anwar SL, Lehmann U.

J Clin Med. 2015 Aug 18;4(8):1631-50. doi: 10.3390/jcm4081631. Review.

Items per page

Supplemental Content

Write to the Help Desk